News

Search:

Public Citizen to FDA: Diabetes Drug Unsafe, Should Be Pulled

0 Likes

The watchdog group Public Citizen is calling on the US Food and Drug Administration (FDA) to yank Novo Nordisk’s diabetes drug Victoza (liraglutide) off the market for safety risks it says “outweigh Read More...

Tags:

Diabetes

FDA

Liraglutide

Novo Nordisk

Public Citizen

Risks

Rosebraugh

Victoza

Wolfe

RF Today is Regulatory Focus' daily news brief. Each edition contains the top global regulatory news stories about pharmaceuticals, medical devices, biotechnology and more. Learn more

Related News

New Regulatory Focus Apps for iPad and iPhone

Stay Connected:

Regulatory Focus is for regulatory professionals written by regulatory professionals.

The publication takes a look at the important topics facing regulatory professionals in a changing global healthcare landscape. From topics ranging from research and development to labeling and marketing, the articles try to analyze, inform, and educate readers about the issues at the forefront of the industry.

Rated as the number one benefit by the members of RAPS, Regulatory Focus strives to provide the best and most current information to regulatory professionals so they can succeed and advance at every stage in their careers.

For questions or comments on our content or to find out more about Regulatory Focus, please visit our About RF page.

News

Public Citizen to FDA: Diabetes Drug Unsafe, Should Be Pulled

Get RF Today